Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer

Modern Pathology

Volumn 30, Issue 4, 2017, Pages 577-586

  Enwere, Emeka K ^a   Kornaga, Elizabeth N ^a   Dean, Michelle ^a   Koulis, Theodora A ^a   Phan, Tien ^a   Kalantarian, Maria ^a   Köbel, Martin ^b   Ghatage, Prafull ^a   Magliocco, Anthony M ^c   Lees Miller, Susan P ^d   Doll, Corinne M ^a  

^a TOM BAKER CANCER CENTRE   (Canada)

^b CALGARY LABORATORY SERVICES   (Canada)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOKERATIN; FORMALDEHYDE; PARAFFIN; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DENSITY; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FLUORESCENCE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATHOLOGIST; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; DISEASE FREE SURVIVAL; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UTERINE CERVIX; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADULT; B7-H1 ANTIGEN; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; CERVIX UTERI; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 85008352242     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2016.221     Document Type: Article

References (41)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386
2. Minig L, Patrono MG, Romero N, et al. Different strategies of treatment for uterine cervical carcinoma stage IB2-IIB. World J Clin Oncol 2014;5:86-92
3. Chemoradiotherapy for Cervical Cancer Meta-Analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008;26:5802-5812
4. Trivedi MS, Hoffner B, Winkelmann JL, et al. Programmed death 1 immune checkpoint inhibitors. Clin Adv Hematol Oncol 2015;13:858-868
5. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455-2465
6. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-562
7. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373: 23-34
8. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-1920
9. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-1741
10. Ukpo OC, Thorstad WL, Lewis JS Jr. B7-H1 expression model for immune evasion in human papillomavirusrelated oropharyngeal squamous cell carcinoma. Head Neck Pathol 2013;7:113-121
11. Cunha LL, Marcello MA, Morari EC, et al. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. Endocr Relat Cancer 2013;20:103-110
12. Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 2016;375: 1856-1867
13. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17: 956-965
14. Mezache L, Paniccia B, Nyinawabera A, et al. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol 2015;28:1594-1602
15. Howitt BE, Sun HH, Roemer MG, et al. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. JAMA Oncol 2016;2:518-522
16. Gevensleben H, Dietrich D, Golletz C, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2016;22:1969-1977
17. Finkelmeier F, Canli O, Tal A, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Eur J Cancer 2016;59:152-159
18. Leng C, Li Y, Qin J, et al. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8(+) T cells. Oncol Rep 2016;35:699-708
19. Tokito T, Azuma K, Kawahara A, et al. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy. Eur J Cancer 2016;55:7-14
20. Doll CM, Aquino-Parsons C, Pintilie M, et al. The significance of tumoral ERCC1 status in patients with locally advanced cervical cancer treated with chemoradiation therapy: a multicenter clinicopathologic analysis. Int J Radiat Oncol Biol Phys 2013;85:721-727
21. Feng X, Li H, Dean M, et al. Low ATM protein expression in malignant tumor as well as cancerassociated stroma are independent prognostic factors in a retrospective study of early-stage hormone-negative breast cancer. Breast Cancer Res 2015;17:65
22. Wimberly H, Brown JR, Schalper K, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 2015;3:326-332
23. McLaughlin J, Han G, Schalper KA, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2016;2:46-54
24. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-268
25. McIntyre JB, Nelson GS, Ghatage P, et al. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma. Gynecol Oncol 2014; 132:188-193
26. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515: 563-567
27. Phillips T, Simmons P, Inzunza HD, et al. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol 2015;23:541-549
28. Romano E, Romero P. The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors. J Immunother Cancer 2015;3:15
29. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-856
30. Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget 2015;6:5449-5464
31. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 2016;8:328rv4
32. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33: 159-174
33. Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol 2016;29:753-763
34. Karim R, Jordanova ES, Piersma SJ, et al. Tumorexpressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin Cancer Res 2009;15:6341-6347
35. Garcia-Teijido P, Cabal ML, Fernandez IP, et al. Tumorinfiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin Med Insights Oncol 2016;10:31-39
36. Bremnes RM, Busund LT, Kilvaer TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol 2016;11:789-800
37. Piersma SJ. Immunosuppressive tumor microenvironment in cervical cancer patients. Cancer Microenviron 2011;4:361-375
38. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature 2013;500:415-421
39. Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated nonsmall-cell lung cancer (POPLAR): a multicentre, openlabel, phase 2 randomised controlled trial. Lancet 2016; 387:1837-1846
40. Botti G, Scognamiglio G, Cantile M. PD-L1 immunohistochemical detection in tumor cells and tumor microenvironment: main considerations on the use of tissue micro arrays. Int J Mol Sci 2016;17:1046
41. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 2016;387:1540-1550